Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy
<b>Background</b>: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with limited treatment options. Tumors harboring the BRAF<sup>V600E</sup> mutation exhibit aggressive behavior and present therapeutic challenges. Although dabrafenib/trametinib (D+T) target the BRAF/MAPK pat...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2026-05-01
|
| Serie: | Life |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/2075-1729/16/5/772 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|